Document is current

Article History

Received: 20 July 2020

Revised: 14 November 2020

Accepted: 24 November 2020

First Online: 11 January 2021

Conflict of interest

: V.J.P. has no conflicts of interest. S.L. is a shareholder of Caelum Biosciences and has received consultant fees from Caelum Biosciences, Bayer, AbbVie, Janssen, Proclara, and Takeda and receives research funding from Karyopharm and Sanofi. D.B. serves on the advisory board for Sanofi. M.L. receives honoraria from Amgen/Onyx, Pfizer, and Prothena; research funding from Amgen/Onyx, BlueBirdBio, Takeda, Pfizer, Celgene, Prothena, Genentech/Roche, Gilead, Janssen, Agios, and Celator; serves on an entity’s board of directors or advisory committee for Takeda, Pfizer, Caelum, Prothena, and Gilead; serves as a consultant for Amgen/Onyx committees, Genentech/Roche, Adaptive, and IQVIA/Jazz Pharmaceuticals. JR serves on the speaker’s bureau for Celgene and Janssen. J.R. serves in an advisory/consulting role for Celgene, Janssen Sanofi, Karyopharm, Antengene, X4 pharmaceuticals, Secura Bio, Adaptive biotechnologies, oncopeptides, and BMS. S.J. reports conflicts of interest with AbbVie, Bristol–Myers Squibb, Celgene, Janssen, Karyopharm, and Merck. A.J. served in a consulting or advisory role for Janssen, received research funding from Janssen and Celgene, and received honoraria from and had travel, accommodations, or other expenses paid or reimbursed by Abbvie, Janssen, and Celgene. R.C. received consulting fees/honoraria from Prothena, Janssen, Amgen, Takeda, Sanofi-Aventis, Unum, Caelum. R.C. received grant/research support from Prothena, Janssen, Takeda, and Karyopharm. M.R. is on the speakers' bureau for Celgene, Takeda, and Janssen. BR received consulting/fees from Janssen, Amgen, and Takeda. V.S. received research support from Celgene, Takeda, Prothena, Janssen; serves on advisory board for Proclara, Caleum, Abbvie. S.S. received research support from Janssen and Sanofi; serves on the advisory boards for Janssen and Prothena and received honoraria from Janssen, Takeda, and Prothena. J.V. has no conflicts of interest to disclose. A.W. has no conflicts of interest to disclose. E.K. received honoraria from Genesis Pharma, Takeda, Janssen, and Amgen. R.F. serves as a consultant for Amgen, BMS, Celgene, Takeda, Bayer, Janssen, Novartis, Pharmacyclics, Sanofi, Merck, Juno, Kite, Aduro, OncoTracker, GSK, and AbbVie. R.F. serves on the Scientific Advisory Board of Adaptive Biotechnologies and OncoTracker. S.W. served as a consultant for Amgen. P.K. is a principal investigator on studies for which Mayo Clinic received clinical research support from Takeda Pharmaceuticals., Amgen, Inc., AbbVie, GlaxoSmithKline, Janssen, and Sanofi. P.K. has served on the scientific advisory board or as a consultant or expert witness for Sanofi-aventis U.S., GlaxoSmithKline, Takeda Pharmaceuticals North America, Inc. with compensation to Mayo Clinic. P.K. has received personal compensation from Pharmacyclics, Cellectar, and Karyopharm for serving on the scientific advisory board or as a consultant. S.W. received research support from Janssen, Fortis, Genentech, and BMS.